Skip to main content
Industry Insights

Industry Insights · Brain–Computer Interface

China prices BCI: invasive implantation fee RMB 6,000–6,600 per case

Innovative medical products often stall at 'approved but un-billable'. BCI is the first to clear that step.

Published:2026-04-22Updated:2026-04-22

Updated
Diagram from device approval to insurance pricing to clinical use
From March approval → April coding and pricing items → provincial guide prices → clinical use: a smooth handoff between approval, payment and clinic. Illustrative.
In short: On 22 April 2026 China's healthcare security administration, in its cumulative 39 batches of pricing guidance, set invasive and non-invasive BCI pricing items for the first time. Several provinces issued guide prices: invasive implantation around RMB 6,000–6,600 per case, non-invasive fitting around RMB 960, with ~10% patient co-pay and most reimbursable. It corresponds to the first domestic invasive BCI approved in March.

Pricing details

  • Invasive BCI implantation fee RMB 6,000–6,600 per case (provincial guide ranges);
  • Non-invasive BCI fitting fee ~RMB 960;
  • ~10% patient co-pay, mostly reimbursable.

Why it's a milestone

Innovative products commonly face 'no billing item' — a registration certificate but no compliant way to charge in hospitals. Setting pricing items institutionally clears the payment path for BCI clinical use.

Speed of execution

From March approval to April coding and price-setting to provincial guide prices, the sequence shows efficient coordination of approval, insurance pricing and clinical use.

The BIO angle

Once payment is unlocked, invasive BCI clinical volume accelerates — and so does demand for long-term implant materials (electrode encapsulation, insulation, tissue interface), exactly where implant-grade medical silicone fits.

FAQ

How much is invasive BCI surgery?

Provinces set the invasive implantation fee around RMB 6,000–6,600 per case and non-invasive fitting around RMB 960; ~10% co-pay, mostly reimbursable.

Is a 'pricing item' the same as 'reimbursement'?

Not exactly. A pricing item first creates a billable service with a guide price — a prerequisite for compliant charging; actual reimbursement ratios depend on local policy.

What does it mean for the industry?

Unlocking payment markedly speeds clinical adoption and volume — a key step in commercializing innovative devices.

Related reading

Browse all insights →

Note: an original analysis compiled from public industry information; figures and conclusions per official/original sources. Not investment advice.

Building in China's medical-device market?

From advanced medical silicone/polymers to material selection, regulatory and supply, BIO helps global and local partners move from selection to landed supply in China.